Cellular protein FGD3 boosts breast cancer chemotherapy and immunotherapy, study findsCellular protein FGD3 boosts breast cancer chemotherapy and immunotherapy, study finds
A naturally-occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report. The protein, FGD3, contributes to the rupture of cancer cells disrupted by these drugs, boosting their effectiveness and enhancing anticancer immunotherapies.
Disparities in Breast Cancer Care for People With DisabilitiesDisparities in Breast Cancer Care for People With Disabilities
This cohort study examines disparities in the diagnosis, treatment, and survival outcomes of patients with breast cancer in Korea both with and without disability.
Researchers aim to disrupt breast cancer line of communication and prevent spreadResearchers aim to disrupt breast cancer line of communication and prevent spread
Cancer Center at Illinois (CCIL) Program Leader Erik Nelson’s lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics.
New study finds Ozempic and Mounjaro protect the heart tooNew study finds Ozempic and Mounjaro protect the heart too
New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% Read More
Saxenda For Weight Loss: How Does It Work And Is It Safe?Saxenda For Weight Loss: How Does It Work And Is It Safe?
Post Content Post Content
As GLP-1 drugs go mainstream, this expert says health is more than a number on a scaleAs GLP-1 drugs go mainstream, this expert says health is more than a number on a scale
Popular weight-loss drugs known as GLP-1s could soon become more affordable for Americans. On Thursday, the Trump administration and two major drugmakers announced an agreement to drastically reduce the cost of the drugs for people enrolled in Medicare and Medicaid, as well as for cash buyers. Popular weight-loss drugs known as GLP-1s could soon become Read More
Wegovy and Ozempic tied to dramatically lower cancer deathsWegovy and Ozempic tied to dramatically lower cancer deaths
GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugs’ anti-inflammatory and metabolic effects contribute to improved outcomes. They’re now calling for clinical trials to Read More
Year in Review: Breast CancerYear in Review: Breast Cancer
(MedPage Today) — Despite tremendous advances in diagnosis, treatment, and survival, breast cancer remains the most common type of cancer in the U.S., with an estimated 317,000 new cases in 2025. The disease burden drives the search for ways to…
Ozempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes DiagnosesOzempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes Diagnoses
(MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic formulation of semaglutide appears in Google searches for weight loss, despite not being FDA-approved for this indication. (NPR) New analyses… (MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic Read More
T-DXd Moves Into Curative Setting in HER2-Positive Breast CancerT-DXd Moves Into Curative Setting in HER2-Positive Breast Cancer
(MedPage Today) — The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology (ESMO) congress, showed that the inclusion of neoadjuvant or adjuvant trastuzumab pathologic complete response…